GlassScriptPhysician profile
Laura J Theis
NPI 1417954017
$1,799.83
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $105 · 2021: $92.34 · 2022: $97.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $302.73 | 2019-2020 | |
| Novo Nordisk INC | $264.38 | 2019-2020 | |
| Allergan, INC. | $215.85 | 2019-2020 | |
| Lilly USA, LLC | $109.90 | 2019-2022 | |
| Glaxosmithkline, LLC. | $107.38 | 2019-2022 | |
| Amgen INC. | $103.94 | 2019-2021 | |
| Mannkind Corporation | $86.02 | 2019 | |
| Merck Sharp & Dohme LLC | $81.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.79 | 2019 | |
| Dexcom, INC. | $41.96 | 2019 | |
| Csl Behring | $33.38 | 2021 | |
| Amarin Pharma, INC. | $28.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.16 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.83 | 2019 | |
| Astellas Pharma US INC | $23.83 | 2019 | |
| Advanced Respiratory, INC | $20.35 | 2019 | |
| Vifor Pharma, INC. | $19.19 | 2019 | |
| Sanofi Pasteur INC. | $17.87 | 2019 | |
| Mylan Specialty L.P. | $16.73 | 2019 | |
| Daiichi Sankyo INC. | $16.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.48 | 2019 | |
| Therapeuticsmd, INC. | $14.75 | 2019 | |
| Abbvie INC. | $14.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Theis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.